SecBot SecBot

CPIX drug pipeline

$5.21
−11.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.6%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketAt least 3-5 years if successful — Phase 3 trials have not yet started for any indication.

ifetroban Updated Jul 13

What to watch

Cumberland is now a pure-play ifetroban development company with ~$100M+ cash post the Apotex sale. The key swing factor is when and how management engages the FDA on a Phase 3 pathway for DMD cardiomyopathy, watch for an FDA meeting announcement or a specific Phase 3 timeline. The stock remains highly speculative with thin liquidity and a mixed analyst consensus (3 Hold, 1 Sell, 2 Strong Sell).

Bull case
  • Ifetroban would be the first therapy specifically indicated for DMD-related heart disease, the leading cause of death in DMD patients, a clear, unmet-need market (source: Pharmacytimes.com, Medthority.com)
  • Phase 2 FIGHT DMD data showed high-dose ifetroban improved LVEF by 3.3% overall and 5.4% vs control at 12 months, the first successful Phase 2 targeting DMD cardiac complications (source: Clinicaltrialsarena.com, Clival.com)
  • FDA granted Fast Track (Feb 2026), Orphan Drug, and Rare Pediatric Disease designations, offering expedited review, tax credits, and potential priority review voucher (source: Drugs.com, Rarediseaseadvisor.com)
Bear case
  • Cumberland is now a single-asset development-stage company with no commercial revenue, any setback in ifetroban's development would be company-threatening (source: SEC DEFM14A filing)
  • Phase 2 FIGHT DMD data came from only 41 patients; the 3.3% LVEF improvement, while positive, is modest and may not translate to a statistically significant Phase 3 result (source: Clival.com, Neurologylive.com)
  • No Phase 3 trial has been designed or initiated for any indication, approval is likely 3-5 years away at minimum, with significant dilution risk (CPIX dilution reported as 390%) (source: Fintel.io, MarketBeat)
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2009 (US).

VIBATIV telavancin Updated Nov 12

What to watch

VIBATIV is a mature, approved antibiotic now owned by Apotex Health Corp. (TSX: APTX) following the July 2026 Cumberland asset sale. There are no upcoming FDA regulatory decisions or pivotal readouts for this drug. For US-listed investors, the drug's commercial performance is now reported by Apotex (Canadian-listed), not by any US-listed company. The previous US owner Cumberland (CPIX) has pivoted to a rare-disease pipeline focused on ifetroban.

Bull case
  • VIBATIV is an FDA-approved antibiotic with a well-established safety and efficacy profile against MRSA and other Gram-positive pathogens, giving it a durable market position.
  • The drug's launch in China (May 2026) opens a large new market; China is the world's second-largest pharmaceutical market.
  • VIBATIV has secured group purchasing agreements with major U.S. hospital group purchasing organizations like Premier and Vizient, supporting steady hospital utilization.
Bear case
  • VIBATIV competes in a crowded antibiotic market against established generics like vancomycin and branded alternatives including daptomycin (Cubicin) and linezolid (Zyvox), limiting pricing power and market share.
  • The drug carries a boxed warning for fetal risk and warnings about nephrotoxicity (kidney injury), which can limit its use versus safer alternatives.
  • VIBATIV is no longer owned by a US-listed company; it was sold to Apotex Health Corp. (TSX: APTX) in July 2026, so US investors cannot directly trade exposure to its commercial performance.

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Mar 31, 2026ifetrobanFast Track−0.6%+0.6%
Mar 31, 2026ifetrobanOrphan drug designation−0.6%+0.6%